As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit ( or

COVID-19 LEOSS Register


Lean European Open Survey on SARS-CoV-2

Status: Active

Purpose / Objectives

Primary Outcome

To identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.


 infection by SARS-CoV-2.

Patient attributes



Inclusion criteria

Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, stool, or blood. Rapid tests are an acceptable alternative.

Exclusion criteria

The study will be governed, announced, and disseminated via ESCMID and other channels across Europe. However, treatment in another country is not a formal exclusion criterion.

Trial design

  • Multicenter
  • Prospective
  • Retrospective





Documents (password protected)

Responsibilities in overall trial

Universität zu Köln

  • Tel. +49 (0)221 478 0

National Coordinating Investigator

Univ.-Prof. Dr. med. Jörg Janne Vehreschild